Advanced search
1 file | 1.01 MB Add to list

The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance

Nele Loret (UGent) , Hannelore Denys (UGent) , Philippe Tummers (UGent) and Geert Berx (UGent)
(2019) CANCERS. 11(6).
Author
Organization
Abstract
Ovarian cancer is the most lethal of all gynecologic malignancies and the eighth leading cause of cancer-related deaths among women worldwide. The main reasons for this poor prognosis are late diagnosis; when the disease is already in an advanced stage, and the frequent development of resistance to current chemotherapeutic regimens. Growing evidence demonstrates that apart from its role in ovarian cancer progression, epithelial-to-mesenchymal transition (EMT) can promote chemotherapy resistance. In this review, we will highlight the contribution of EMT to the distinct steps of ovarian cancer progression. In addition, we will review the different types of ovarian cancer resistance to therapy with particular attention to EMT-mediated mechanisms such as cell fate transitions, enhancement of cancer cell survival, and upregulation of genes related to drug resistance. Preclinical studies of anti-EMT therapies have yielded promising results. However, before anti-EMT therapies can be effectively implemented in clinical trials, more research is needed to elucidate the mechanisms leading to EMT-induced therapy resistance.
Keywords
FALLOPIAN-TUBE EPITHELIUM, CISPLATIN RESISTANCE, DRUG-RESISTANCE, STEM-CELLS, E-CADHERIN, TUMOR MICROENVIRONMENT, INDUCED APOPTOSIS, TRANSITION, EMT, PROMOTES, ovarian cancer, epithelial-to-mesenchymal transition (EMT), mesenchymal-to-epithelial transition (MET), peritoneal metastasis, therapy resistance, cancer stem cell (CSC)

Downloads

  • 4185 19Loret.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.01 MB

Citation

Please use this url to cite or link to this publication:

MLA
Loret, Nele et al. “The Role of Epithelial-to-mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance.” CANCERS 11.6 (2019): n. pag. Print.
APA
Loret, N., Denys, H., Tummers, P., & Berx, G. (2019). The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. CANCERS, 11(6).
Chicago author-date
Loret, Nele, Hannelore Denys, Philippe Tummers, and Geert Berx. 2019. “The Role of Epithelial-to-mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance.” Cancers 11 (6).
Chicago author-date (all authors)
Loret, Nele, Hannelore Denys, Philippe Tummers, and Geert Berx. 2019. “The Role of Epithelial-to-mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance.” Cancers 11 (6).
Vancouver
1.
Loret N, Denys H, Tummers P, Berx G. The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance. CANCERS. 2019;11(6).
IEEE
[1]
N. Loret, H. Denys, P. Tummers, and G. Berx, “The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance,” CANCERS, vol. 11, no. 6, 2019.
@article{8625740,
  abstract     = {Ovarian cancer is the most lethal of all gynecologic malignancies and the eighth leading cause of cancer-related deaths among women worldwide. The main reasons for this poor prognosis are late diagnosis; when the disease is already in an advanced stage, and the frequent development of resistance to current chemotherapeutic regimens. Growing evidence demonstrates that apart from its role in ovarian cancer progression, epithelial-to-mesenchymal transition (EMT) can promote chemotherapy resistance. In this review, we will highlight the contribution of EMT to the distinct steps of ovarian cancer progression. In addition, we will review the different types of ovarian cancer resistance to therapy with particular attention to EMT-mediated mechanisms such as cell fate transitions, enhancement of cancer cell survival, and upregulation of genes related to drug resistance. Preclinical studies of anti-EMT therapies have yielded promising results. However, before anti-EMT therapies can be effectively implemented in clinical trials, more research is needed to elucidate the mechanisms leading to EMT-induced therapy resistance.},
  articleno    = {838},
  author       = {Loret, Nele and Denys, Hannelore and Tummers, Philippe and Berx, Geert},
  issn         = {2072-6694},
  journal      = {CANCERS},
  keywords     = {FALLOPIAN-TUBE EPITHELIUM,CISPLATIN RESISTANCE,DRUG-RESISTANCE,STEM-CELLS,E-CADHERIN,TUMOR MICROENVIRONMENT,INDUCED APOPTOSIS,TRANSITION,EMT,PROMOTES,ovarian cancer,epithelial-to-mesenchymal transition (EMT),mesenchymal-to-epithelial transition (MET),peritoneal metastasis,therapy resistance,cancer stem cell (CSC)},
  language     = {eng},
  number       = {6},
  pages        = {22},
  title        = {The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance},
  url          = {http://dx.doi.org/10.3390/cancers11060838},
  volume       = {11},
  year         = {2019},
}

Altmetric
View in Altmetric
Web of Science
Times cited: